Summary of performance of multiplexed markers on Bio-Rad and Millipore
Bio-Rad markers with acceptable performancea | Bio-Rad markers with <25% detectabilityb | Millipore markers with acceptable performance | Millipore markers with acceptable performancea | Millipore markers with <25% detectabilityb |
---|---|---|---|---|
A2M | B_NGF | Amylin_Total | MIP_1D | Eotaxin 3 |
CRP | GM_CSF | BCA_1 | PP | Ghrelin |
CTACK | IFNA2 | CCL19_MIP3B | PYY | IL_20 |
C Peptide | IL_12P40 | CCL20_MIP3A | SAA | IL_21 |
Eotaxin | IL_15 | CKINE | SAP | IL_28a |
Ferritin | IL_1A | CRP | SCD30 | IL_3 |
FGF_Basic | IL_2 | CTACK | SCD40L | IL_4 |
Fibrinogen | IL_3 | CXCL11_I_TAC | SCF | IL_5 |
Ghrelin | LIF | CXCL6_GCP2 | SDF_1A | M_CSF |
GIP | MCP_3 | CXCL9_MIG | SEGFR | XCL1_Lympho |
GLP_1 | TNFB | C_Peptide | SGP130 | Millipore markers |
Glucagon | EGF | SILRII | with >20% CVc | |
GRO | Bio-Rad markers | ENA_78 | SIL_1RI | |
Haptoglobin | with >20% CVc | Eotaxin | SIL_2RA | GM_CSF |
HGF | Eotaxin_2 | SIL_4R | IL_10 | |
IFNG | B_NGF | FGF_Basic | SIL_6R | IL_12P70 |
IL_16 | GM_CSF | FIT_3_Ligand | SRAGE | IL_13 |
IL_18 | G_CSF | Fractalkine | STNFRI | IL_15 |
IL 1RA | IL_10 | GIP | STNFRII | IL_17 |
IL 2RA | IL_12P70 | GLP_1 | SVEGFR1 | IL_1B |
IL_6 | IL_13 | Glucagon | SVEGFR2 | IL_1RA |
IL_8 | IL_15 | GRO | SVEGFR3 | IL_2 |
IL 9 | IL_17 | G_CSF | TARC | IL_21 |
Insulin | IL_1A | IFNA2 | TNF-α | IL_23 |
IP_10 | IL 1B | IFNG | TPO | IL_28A |
Leptin | IL_2 | IL_11 | TRAIL | IL_3 |
MCP_1MC | IL_4 | IL_12P40 | TSLP | IL_4 |
MIF | IL_5 | IL_16 | VEGF | IL_5 |
MIG | IL_7 | IL_1A | IL_6 | |
MIP_1B | LIF | IL_29_IFNG1 | IL_7 | |
M_CSF | MCP_3 | IL_33 | IL_9 | |
PAI_1 | MIP 1A | IL_8 | I_309 | |
PCT | TNF_B | INSULIN | M_CSF | |
PDGF_BB | TPA | IP_10 | TGFA | |
Rantes | LEPTIN | TNF-B | ||
Resistin | LIF | XCL1_Lympho | ||
SAA | MCP_1 | |||
SAP | MCP_2 | |||
SCF | MCP_3 | |||
SCGF_B | MCP_4 | |||
SDF_1A | MDC | |||
TNF-α | MIP_1A | |||
TRAIL | MIP_1B | |||
VEGF | ||||
Visfatin |
aAcceptable performance was defined as (i) being detectable in greater than 25% of the 100 samples on all 3 specimen types and (ii) across-batch CVs of less than 20% for blinded duplicates on at least 2 of the 3 specimen types.
bMarkers with less than 25% detectability on at least 1 of 3 (serum, heparin plasma, and EDTA plasma) specimen types.
cMarkers with CVs for across-batch duplicates greater than 20% on 2 or more of 3 specimen types. CVs were calculated for 20 blinded duplicate samples for each specimen type that were placed across different batches.